Pfizer Korea and Bristol-Meyers Squibb Pharmaceutical Korea faced a one-month drug import suspension due to poor packaging.

The Ministry of Food and Drug Safety said it suspended the two companies from importing Viviant Tab. 20mg (ingredient: bazedoxifene acetate) and Baraclude Tab. 0.5mg (ingredient: entecavir), respectively, for one month, starting on Monday.

Pfizer Korea imported Viviant, ran quality tests, and sold the products without knowing that some of them were in damaged blister packs. For neglecting quality control, the ministry suspended the imports of Viviant for a month.

The authorities also found that some of BMS Pharmaceutical Korea’s Baraclude Tab. packages did not contain the full amount of drugs.

The medicine comes in a paper box with three blister packs each having 10 tablets. However, the ministry found that one blister pack did not contain any tablet. The government also suspended BMS Pharmaceutical Korea’s imports of Baraclude for one month, citing neglect in quality control.